Surgery Chemotherapy Articles & Analysis
13 news found
Standard treatment options for RCC are surgery, radiation, chemotherapy, targeted therapy or immunotherapy. ...
Current treatments for CRC include surgery and chemotherapy in early stages of disease and chemotherapy, biologics and targeted therapies in later stages. ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM patients as part ...
The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. The VACCS just completed year three of the planned five year trial. It is being conducted at three leading canine oncology centers – the Flint Animal Cancer Center at Colorado State University, the School of Veterinary Medicine at University of Wisconsin-Madison and the University of ...
ByCalviri
LONDON, February 7, 2022– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 201 Phase 1b trial of PolyPEPI1018, the Company’s lead product candidate, as an add-on to standard-of-care third-line ...
When looking at key risk factors for BCRL, including body weight, stage of cancer, type of cancer surgery, lymph node dissection, chemotherapy, and radiation, the benefit of using L-Dex monitoring was consistent and showed the utility of L-Dex across a large group of breast cancer ...
The current standard of care for patients with operable malignant glioma tumors is surgical removal of the tumor followed by radiation and chemotherapy. Traditional radiation is delivered in as many as 30 treatments extending over a period of several weeks. ...
We are glad to announce that scientists from our biotechnology company BlueSky Immunotherapies GmbH (Ltd.) have achieved great success in completely and permanently eliminating equine sarcoids and bovine papillomavirus that causes this aggressive form of skin cancer that horses often suffer from. By using its proprietary delNS technology, BlueSky Immunotherapies has created a viral vector ...
The center offers the latest and most advanced diagnostics and treatments in surgery, chemotherapy, and radiation therapy. It attains its mission through an innovative study of cancer, thoughtful and compassionate care, specialized treatment options, and procedures. ...
ByCalviri
Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PolyPEPI1018, the Company’s lead product candidate, as an add-on to third-line chemotherapy (TAS-102) for the treatment of patients with late-stage metastatic colorectal cancer (mCRC). ...
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces they have submitted an Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) to initiate First-in-Human (FiH) studies of the VectRx™ System in patients with pancreatic cancer being treated with standard of care ...
Surgical removal, chemotherapeutics and/or radiation are the primary cancer treatments. Unfortunately, both chemotherapy and radiation present the patient with debilitating systemic side effects. In addition, patient comorbidity often excludes patients as candidates for surgery, chemotherapy and/or radiation. Our ability to cause intracellular ...
The ability to improve drug access to the tumor for the chemotherapy and enhance the anti-neoplastic effects of radiation therapy, if proven by the NTO device, may potentiate both therapies to benefit the patient. ...